|
Session 23
Oral Abstracts
Antiretroviral Therapy II: New Insights and Treatment Strategies
Tuesday, 10 am - 12:30 pm
Room: Lecture Hall |
Moderators: |
Scott Hammer
Columbia Univ Coll of Physicians & Surgeons, NY, US
Sharon Walmsley
Toronto Gen Hosp, Canada
|
| 10:00 am 101 |
Predictors of HIV Disease Progression in Patients Who Stop ART with CD4 Cell Counts >350 cells/mm3
Daniel Skiest*1, D Havlir2, R Coombs3, E Adams4, P Cain5, T Petersen6, D Rusin7, C Jennings8, K Robertson9, D Margolis9, and the ACTG 5170 Team
1Baystate Med Ctr, Springfield, MA, US; 2Univ of California, San Francisco, US; 3Univ of Washington, Seattle, US; 4NIAID, NIH, DHHS, Bethesda, MD, US; 5Stanford Univ Med Ctr, CA, US; 6Univ of Texas Southwestern Med Ctr, Dallas, US; 7Frontier Sci & Tech Res Fndn, Amherst, NY, US; 8Rush Presbyterian/St Luke's Med Ctr, Chicago, IL, US; and 9Univ of North Carolina at Chapel Hill, US |
| 10:15 am 102 |
CD4-guided Scheduled Treatments Interruptions Compared to Continuous Therapy: Results of the Staccato Trial
Jintanat Ananworanich*1, A Gayet-Ageron2, M Le Braz2, W Prasithsirikul3, P Chetchotisakd4, S Kiertiburanakul5, P Phanuphak1, D Cooper6, K Ruxrungtham1, B Hirschel2, and the Staccato Study Group
1HIV Netherlands Australia Thailand Res Collaboration, Bangkok; 2Geneva Univ Hosp, Switzerland; 3Bamrasnaradura Inst, Nonthaburi, Thailand; 4Khon Kaen Univ, Thailand; 5Mahidol Univ, Bangkok, Thailand; and 6Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia |
| 10:30 am 103 |
Final Results of a Randomized, Controlled Trial of Structured Treatment Interruptions vs Continuous HAART in Chronic HIV-infected Subjects with Persistent Suppression of Viral Replication
Lucia Palmisano*, M Giuliano, R Bucciardini, M Andreotti, V Fragola, C Galluzzo, M Pirillo, M Mancini, L Weimer, S Vella, and the Italian ISS PART Clin Ctrs
Inst Superiore di Sanità, Rome, Italy |
| 10:45 am 104 |
Structured Treatment Interruptions in HIV-infected Patients with High CD4 Cell Counts and Virologic Suppression: Results of a Prospective, Randomized, Open-label Trial (Window - ANRS 106)
Bruno Marchou*1, P Tangre2, I Charreau2, J Izopet1, P M Girard3, T May4, J M Ragnaud5, J P Aboulker2, J M Molina6, and ANRS 106 Study Group
1Hosp Purpan, Toulouse, France; 2INSERM SC10, Villejuif, France; 3Hosp St Antoine, Paris, France; 4Hosp Brabois, Vandoeuvre les Nancy, France; 5CHU Pellegrin, Bordeaux, France; and 6Hosp St Louis, Paris, France |
| 11:00 am 105LB |
The CD4-guided Strategy Arm Stopped in a Randomized Structured Treatment Interruption Trial in West-African Adults: ANRS 1269 Trivacan Trial
Christine Danel*1, R Moh1, S Sorho1, A Minga1, A Anzian1, O Ba-Gomis1, D Gabillard2, E Bissagnene1, R Salamon2, X Anglaret2, and ANRS 1269 Study Group
1Ctr Hosp Univ de Treichville, Abidjan, Côte d’Ivoire and 2Univ Bordeaux 2, France |
| 11:15 am 106LB |
Episodic CD4-Guided Use of ART Is Inferior to Continuous Therapy: Results of the SMART Study
Wafaa El-Sadr* and J Neaton
for the SMART Study Investigators |
| 11:30 am 107LB |
Efficacy and Safety of Atazanavir-based Therapy in Antiretroviral Naive HIV-1 Infected Subjects, Both with and without Ritonavir: 48-week Results from AI424-089
Niel Malan*1, E Krantz2, N David3, K Kastango4, D Frederick4, M Matthew4, S Schnittman4, J Hammond4, and the -089 Study Group
1Triple M Res, Port Elizabeth, South Africa; 2Quinta-Res, Bloemfontein, South Africa; 3Cape Town, South Africa; and 4Bristol-Myers Squibb Pharma Res Inst, Wallingford, CT, US |
| 11:45 am 108LB |
A Prospective, Open-label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy after Sustained Virologic Suppression (ACTG 5201)
Susan Swindells*1, T Wilkin2, G DiRienzo3, C Fletcher4, G Thal5, H Huang3, E Werner4, J McKinnon6, J Mellors6, and the AIDS Clin Trials Group
1Univ of Nebraska Med Ctr, Omaha, US; 2Weill Med Coll, Cornell Univ, New York, NY, US; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 4Univ of Colorado Hlth Sci Ctr, Denver, CO, US; 5Bristol-Myers Squibb, Plainsboro, NJ, US; and 6Univ of Pittsburgh Sch of Med, PA, US |
| 12:00 pm 109LB |
Safety of Nevirapine Compared to Abacavir on a Background of Zidovudine/Lamivudine as First-line Antiretroviral Therapy: A Randomized Double-blind Trial
Paula Munderi and the DART Trial Team
Med Res Council, Uganda Res Unit on AIDS, Entebbe |
| 12:15 pm 110 |
Viral Decay Rates in Men and Women Receiving Triple-nucleoside or Efavirenz-containing ART: Viral Dynamics Substudy of ACTG A5095
Kathleen Squires*1, H Ribaudo2, D Kuritzkes3, C Shikuma4, W Meyer5, K Klingman6, R Gulick7, and ACTG A5166s and ACTG A5095
1Thomas Jefferson Univ, Philadelphia, PA, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Brigham & Women's Hosp, Harvard Med Sch, Boston, MA, US; 4Univ of Hawaii, Honolulu, US; 5Quest Diagnostics, Baltimore, MD, US; 6Div of AIDS, NIAID, NIH, DHHS, Bethesda, MD, US; and 7Cornell Univ, New York, NY, US |
|
